# A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

> **NCT01294683** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 977 (actual)

## Conditions studied

- Primary Hypercholesterolemia
- Dyslipidemia

## Interventions

- **DRUG:** Simvastatin
- **DRUG:** Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)
- **DRUG:** Extended Release (ER) niacin/laropiprant (N/LRPT)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01294683
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02-04
- **Primary completion:** 2012-01-17
- **Final completion:** 2012-01-17
- **Target enrollment:** 977 (ACTUAL)
- **Last updated:** 2018-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01294683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01294683, "A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01294683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*